Background Vedolizumab (VDZ) demonstrated efficacy in Crohn's disease (CD) and
ulcerative colitis (UC) in the GEMINI trials. Our aim was to evaluate the efficacy of VDZ at …

Recent advancement in the understanding of the pathophysiology of inflammatory bowel
disease has seen an expansion in therapeutic options. Vedolizumab, a selective α4β7 …

Background & Aims Patients with Crohn's disease (CD) or ulcerative colitis (UC) often
receive combination therapy with an immunomodulator and tumor necrosis factor …

Summary Background The management of Crohn's disease patients with perianal lesions
and anti‐TNF failure is challenging. Aims To assess the effectiveness of vedolizumab in …

Background Vedolizumab (VDZ) has demonstrated long-term efficacy in Crohn's disease
(CD) and ulcerative colitis (UC) in phase III trials. Aims Our aim was to evaluate the efficacy …

Despite current guidelines, the optimal treatment of patients with inflammatory bowel
disease (IBD) remains challenging. The available medications are not without risk and there …

Background Management of inflammatory bowel disease (IBD) involves biological agents,
often in combination with thiopurines or methotrexate. The aim of our study was to compare …

As the incidence of inflammatory bowel disease (IBD) rises and the global population ages,
the number of older people living with these conditions will inevitably increase. The …

Background: Ustekinumab and vedolizumab represent both valid therapeutic options in
patients with Crohn's Disease. Data comparing the safety and efficacy of these drugs are …

Drug-induced liver injury is a rare but clinically important diagnosis. Vedolizumab is an α4β7
integrin inhibitor recently approved for use in patients with moderate-to-severe inflammatory …